Primary management of DCM includes beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) without or with neprolysin inhibition (ARNI), and sodium-glucose cotransporter 2 (SGLT2) inhibitors [10, 11]. Here, SLC5A2 is linked to familial dilated cardiomyopathy.